OR WAIT 15 SECS
© 2020 MJH Life Sciences and BioPharm International. All rights reserved.
© 2020 MJH Life Sciences™ and BioPharm International. All rights reserved.
RNA is easier to manipulate than DNA but challenging to deliver to the right cells.
Advances in preclinical development can reduce development cost.
October 30, 2020
FDA published guidance for submitting standardized study data in electronic format.
October 29, 2020
Samsung Biologics has adopted Solentim’s cell seeding and cell metric platforms at its new R&D center in San Francisco, CA.
October 20, 2020
Orgenesis has completed its previously announced acquisition of Koligo Therapeutics with the additional acquisition of Tissue Genesis’ cell isolation technology, Icellator.
October 16, 2020
Bio/Pharma companies are galvanized to develop COVID-19 therapies under FDA’s acceleration program.
AFI representatives of the process validation working group explore and define key elements for an enhanced approach to process validation for sterile liquid and freeze-dried forms.
October 15, 2020
The IQ Consortium marks a decade of impactful innovation of collaboration through a network of pharmaceutical companies driving change for the bio/pharmaceutical industry.
October 02, 2020
Advances in preclinical development play a crucial role in reducing cost for developing biosimilars.
October 01, 2020
A data-integrity risk assessment tool has been developed for use with standalone R&D data-acquisition and processing software.
The acquisition will support the accelerated commercialization of Kyslecel (autologous pancreatic islets), Koligo’s personalized cell therapy for treating pancreatitis.
September 22, 2020
Moderna and Chiesi Group are collaborating on the discovery and development of mRNA therapeutics to treat pulmonary arterial hypertension.
September 18, 2020
The collaboration will expand the manufacturing capacity for lenzilumab, a COVID-19 therapeutic candidate, in advance of a potential Emergency Use Authorization in 2020.
The agreement will Increase global manufacturing capacity for Novavax’s vaccine candidate, NVX-CoV2373, to more than two-billion annualized doses when at full capacity in 2021.
The agreement between the two companies will significantly increase global supply capacity for Lilly's potential COVID-19 treatments.
September 15, 2020
The companies will focus on the development and commercialization of Seattle Genetics’ ladiratuzumab vedotin and TUKYSA (tucatinib).
September 09, 2020
Catalent’s Redwood Bioscience subsidiary will develop antibody-drug conjugates (ADCs) for Exelixis using Catalent’s proprietary SMARTag site-specific bioconjugation technology.
September 08, 2020
As public confidence in the drug development process waivers, leading vaccine developers promise to adhere to scientific and regulatory principles.
September 02, 2020
The companies have entered into a strategic partnership for the CMC development and manufacturing of Ansun’s biologics pipeline.
September 01, 2020
Amid high expectations for a COVID-19 vaccine, biopharma readies production capacity, weighs external pressures.
August 28, 2020
The collaboration includes an integrated program that encompasses formulation development, drug substances, and drug product manufacturing.
The register supports cross-functional teams of chemists and biologists in developing non-natural, chemically-modified therapeutics for drug discovery.